Skip to content

LSD: all studies

Page 155 of 282: studies 1,541 to 1,550 of 2,815, newest first. Back to the LSD overview

Research

Psychedelics in functional disorders: A scoping review

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 10, 2026 Chiranth Bhagavan, Olivia Carter, Alexander Bryson et al. 1 citation

Functional disorders, characterised by symptoms unexplained by organic disease, impose a significant burden on individuals and healthcare systems. Existing treatments are limited in efficacy, with no effective pharmacotherapies. There is growing evidence supporting the treatment potential of psychedelics in neuropsychiatric conditions, including several distinct functional disorders. This...

DOI: 10.1016/j.pnpbp.2026.111642 (opens in new tab) Observational study Clinical trial Functional impairment Medline +4

Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature

Deviant Behavior February 9, 2026 Blake Beaton 2 citations

Microdosing is a novel approach to the consumption of classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin that emerged in recent years. Unlike traditional illicit substance use, which often seeks euphoric experiences, microdosing deliberately avoids such effects in pursuit of self-enhancement. This practice has grown in popularity likely due to the perceived...

DOI: 10.1080/01639625.2026.2624690 (opens in new tab) Qualitative research Qualitative analysis Data collection Engineering ethics +3

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.

Journal of Psychopharmacology February 5, 2026 Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.

Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...

Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models

Research Square February 2, 2026 Ziv Ben-Zion, Guy Simon, Teddy Lazebnik preprint

Abstract Large language models (LLMs) are increasingly consulted by individuals for support during psychedelic experiences ("trip sitting"), yet no framework exists to evaluate whether these models can accurately simulate or safely respond to altered states of consciousness. We aimed to determine if LLMs can be induced to generate narratives resembling human psychedelic experiences and to...

Psychedelika und Entaktogene: Neue Hoffnung für therapieresistente Störungen?

Nervenheilkunde February 1, 2026 Dimitris Repantis, Michael Koslowski, Felix Betzler et al.

Zusammenfassung Psychedelika wie Psilocybin und LSD durchlaufen eine bemerkenswerte Geschichte, die von frühen psychiatrischen Anwendungen über den Freizeitgebrauch und die Prohibition in den 70er Jahre bis zur aktuellen Wiederentdeckung in klinischen Studien reicht. MDMA wird seit etwa 15 Jahren für die Behandlung der posttraumatischen Belastungsstörung evaluiert. In der Behandlung werden...

Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research.

Neuroscience & Biobehavioral Reviews February 1, 2026 Mallet R Reid, Jonathan Song, Kevin F. Boehnke et al.

People of color have been significantly underincluded in psychedelic-assisted therapy (PAT) research, despite facing challenges commonly addressed in PAT and often more severe symptoms. It may be the case that people of color are underincluded because PAT researchers have not used approaches designed to promote sample diversity. Community-engaged research (CEnR) is a research paradigm that has...

DOI: 10.1016/j.neubiorev.2025.106516 (opens in new tab) Full text (opens in new tab) Community-engaged research Psychedelic assisted therapy

Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?

Journal of Affective Disorders February 1, 2026 Lauren N Vale, Maya Ibrahim, Leonardo Fávaro-pereira et al. 1 citation

In recent years psychedelics have gained popularity and potential promise in the field of mental health, but for patients diagnosed with bipolar disorder (BD), fears of emerging manic or psychotic symptoms have caused investigators to exclude them from psychedelic research. In this observational study, we explore the motivations, expectations, and personality characteristics of individuals with...

DOI: 10.1016/j.jad.2025.120437 (opens in new tab) Full text (opens in new tab) Attitudes towards psychedelics Bipolar disorder Mental health treatment Mood disorders +1

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

Journal of the Royal Society of New Zealand February 1, 2026 Neil McNaughton, Shabah M. Shadli, Ben Beaglehole et al.

The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...

Hallucinations Induced by Psychoactive Drugs: Mechanisms, Consequences, and Therapeutic Interventions

Acta Scientific Neurology February 1, 2026

Millions of people worldwide experience hallucinations caused by psychoactive substances.These hallucinations are a serious problem for both health care and society.The main culprits are hallucinogens like psilocybin, phencyclidine (PCP), methamphetamine, and lysergic acid diethylamide (LSD).These substances lead to perceptual changes characterized by sensory experiences that happen without any...

DOI: 10.31080/asne.2025.09.0874 (opens in new tab) Psychosis Disease Medline Schizophrenia object-oriented programming +1

Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies

Biological Psychiatry February 1, 2026 Jin Zhang, Cong Lin, Xinyou Lv et al. 1 citation

Classic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), have emerged as potent modulators of neuroplasticity and metaplasticity in the adult brain, offering novel therapeutic strategies for neuropsychiatric disorders. Recent findings reveal that beyond their transient psychotropic effects, these compounds activate serotonin 5-HT2A receptors...